Literature DB >> 8345815

Prevalence and pathophysiology of impaired glucose tolerance in three different high-risk white groups.

R C Page1, E K Walravens, J C Levy, I M Stratton, R C Turner.   

Abstract

Insulin resistance and beta-cell function were assessed by a continuous infusion of glucose in the following three groups of white subjects at risk of developing impaired glucose tolerance and diabetes: 41 subjects who were the offspring of patients with type II diabetes, 26 general-population subjects with an increased fasting plasma glucose level of at least 5.6 mmol/L on screening, and 22 subjects who had had gestational diabetes but were now nondiabetic. Subjects had a mean (+/- 1 SD) age of 43 +/- 9 years and a body mass index (BMI) of 27 +/- 5 kg/m2. Subjects with previously increased fasting glucose levels were significantly more insulin resistant than a control group, taking into account BMI, age, and gender (% normal insulin sensitivity [%], 59 [50 to 79] v 87 [73 to 96]; P < .005), and previously gestationally diabetic subjects showed greater impairment of beta-cell function (% normal beta-cell function [% beta], 69 [60 to 87] v 97 [89 to 105]; P < .005). Diabetes (defined by World Health Organization criteria) or impaired glucose tolerance (defined as an achieved plasma glucose concentration [APG] > 95th percentile of an age- and weight-matched population) was identified in 22% of family members, 31% of fasting hyperglycemic subjects, and 41% of previously gestationally diabetic subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8345815     DOI: 10.1016/0026-0495(93)90003-7

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  1 in total

1.  Prevalence of diabetes mellitus and impaired glucose tolerance in parents of women with gestational diabetes.

Authors:  J A McLellan; B A Barrow; J C Levy; M S Hammersley; A T Hattersley; M D Gillmer; R C Turner
Journal:  Diabetologia       Date:  1995-06       Impact factor: 10.122

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.